Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Medroxyprogesterone - InKine

Drug Profile

Medroxyprogesterone - InKine

Alternative Names: Colirest; Hematrol

Latest Information Update: 17 Sep 2007

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator InKine Pharmaceutical; University of Pennsylvania
  • Class Anti-inflammatories; Antineoplastics; Hormonal replacements; Progesterone congeners; Progestogen-only oral contraceptives
  • Mechanism of Action Interleukin 6 inhibitors; Progesterone receptor agonists; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autoimmune haemolytic anaemia; Crohn's disease; Idiopathic thrombocytopenic purpura; Ulcerative colitis

Most Recent Events

  • 04 Oct 2005 InKine Pharmaceutical has been acquired by Salix Pharmaceuticals
  • 01 Sep 2005 No development reported - Phase-II for Crohn's disease in USA (PO)
  • 01 Sep 2005 No development reported - Phase-II for Ulcerative colitis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top